Abstract
The study of radiation mitigators/protectors for use in cancer treatment and management is complex as they must reduce normal tissue toxicity without reducing tumor cell kill. The known toxicology, pharmacokinetic, and mechanistic data for the proposed agent will direct investigators to the appropriate stage of preclinical development. Overall, we hope that this Workshop commentary facilitates the transition of radiation mitigators/protectors into clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
